Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

DEB025 · DEBIO-025

Small molecule · developed by Debiopharm International SA

Phase 1 Most advanced trial (none active)
1 Registered trials

What is DEB025?

DEB025 (also known as Debio-025) is a drug studied in hepatitis C virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DEBIO-025
Drug type
Small molecule
Therapy area
Infectious disease
Developer
Debiopharm International SA
In trials of
ENTA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
VBP9099AA6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02173574 Phase 1 Hepatitis C Virus Completed ENTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis C Virus

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.